tetano
Editor, Senior Moderator
Expert Rev Mol Diagn
. 2022 Oct 12.
doi: 10.1080/14737159.2022.2135434. Online ahead of print.
Diagnostic accuracy of clinically applied nanoparticle-based biosensors at detecting SARS-CoV-2 RNA and surface proteins in pharyngeal swabs compared to RT-PCR as a reference test
Milad Shirvaliloo[SUP] 1 2 [/SUP], Roghayeh Sheervalilou[SUP] 3 [/SUP], Ehsan Ahmadpour[SUP] 1 4 [/SUP], Saeid Safiri[SUP] 5 6 [/SUP], Hossein Bannazadeh Baghi[SUP] 1 7 [/SUP]
Affiliations
Abstract
Introduction: : Nanoparticle-based biosensors (NPBs) are point-of-care diagnostic platforms that can be used for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high accuracy.
Areas covered: : EBSCOhost Web, Embase, ProQuest, PubMed/MEDLINE, Scopus, Web of Science, and WHO Global Literature on Coronavirus Disease 2019 (COVID-19) were searched for relevant records published from November 1, 2019 to April 30, 2022. Records reporting original data on the accuracy of clinically applied nanoparticle-based biosensors at detecting SARS-CoV-2 RNA and surface proteins from pharyngeal swab specimens were considered. Findings were reported based on the PRISMA 2020 statement. The QUADAS-2 tool was used for assessment of quality and risk of bias among the included studies.
Expert opinion: : A total of 50 relevant records were identified, of which 13 were included. The included studies explored the diagnostic performance of 13 clinically applied distinct nanoparticle-based biosensors in a total of 789 pharyngeal swabs collected from 376 COVID-19 patients and 413 otherwise healthy individuals. The mean sensitivity, specificity and accuracy were 97.07%, 94.43% and 96.91%, respectively, in comparison to RT-qPCR as the reference test. Considering their ease-of-operation, portability, low-cost manufacturing, NPBs could be considered suitable candidate diagnostic platforms for substituting RT-qPCR.
Keywords: Biosensors; COVID-19; SARS-CoV-2; coronavirus disease 2019; diagnostic accuracy; nanobiosensors; nanoparticle-based biosensors; sensitivity; specificity.
. 2022 Oct 12.
doi: 10.1080/14737159.2022.2135434. Online ahead of print.
Diagnostic accuracy of clinically applied nanoparticle-based biosensors at detecting SARS-CoV-2 RNA and surface proteins in pharyngeal swabs compared to RT-PCR as a reference test
Milad Shirvaliloo[SUP] 1 2 [/SUP], Roghayeh Sheervalilou[SUP] 3 [/SUP], Ehsan Ahmadpour[SUP] 1 4 [/SUP], Saeid Safiri[SUP] 5 6 [/SUP], Hossein Bannazadeh Baghi[SUP] 1 7 [/SUP]
Affiliations
- PMID: 36224104
- DOI: 10.1080/14737159.2022.2135434
Abstract
Introduction: : Nanoparticle-based biosensors (NPBs) are point-of-care diagnostic platforms that can be used for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high accuracy.
Areas covered: : EBSCOhost Web, Embase, ProQuest, PubMed/MEDLINE, Scopus, Web of Science, and WHO Global Literature on Coronavirus Disease 2019 (COVID-19) were searched for relevant records published from November 1, 2019 to April 30, 2022. Records reporting original data on the accuracy of clinically applied nanoparticle-based biosensors at detecting SARS-CoV-2 RNA and surface proteins from pharyngeal swab specimens were considered. Findings were reported based on the PRISMA 2020 statement. The QUADAS-2 tool was used for assessment of quality and risk of bias among the included studies.
Expert opinion: : A total of 50 relevant records were identified, of which 13 were included. The included studies explored the diagnostic performance of 13 clinically applied distinct nanoparticle-based biosensors in a total of 789 pharyngeal swabs collected from 376 COVID-19 patients and 413 otherwise healthy individuals. The mean sensitivity, specificity and accuracy were 97.07%, 94.43% and 96.91%, respectively, in comparison to RT-qPCR as the reference test. Considering their ease-of-operation, portability, low-cost manufacturing, NPBs could be considered suitable candidate diagnostic platforms for substituting RT-qPCR.
Keywords: Biosensors; COVID-19; SARS-CoV-2; coronavirus disease 2019; diagnostic accuracy; nanobiosensors; nanoparticle-based biosensors; sensitivity; specificity.